<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ISOTRETINOIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ISOTRETINOIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Topical treatment of mild to moderate acne</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1&#8211;2 times a day, to be applied thinly.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe acne (under expert supervision)</span>,
                <span class="indication">Acne which is associated with psychological problems (under expert supervision)</span>,
                <span class="indication">Acne which has not responded to an adequate course of a systemic antibacterial (under expert supervision)</span>,
                <span class="indication">Acne with scarring (under expert supervision)</span>,
                <span class="indication">Systemic treatment of nodulo-cystic and conglobate acne (under expert supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 500 micrograms/kg daily in 1&#8211;2 divided doses, increased if necessary to 1 mg/kg daily for 16&#8211;24 weeks, repeat treatment course after a period of at least 8 weeks if relapse after first course; maximum 150 mg/kg per course.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Contra-indicated in pregnancy (teratogenic).</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Avoid&#8212;further impairment may occur.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>In severe impairment, reduce initial dose (e.g. 10&#8239;mg daily) and increase gradually up to 1&#8239;mg/kg daily as tolerated.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> anaemia, arthralgia, dryness of eyes (with blepharitis and conjunctivitis), dryness of lips (sometimes cheilitis), dryness of nasal mucosa (with epistaxis), dryness of pharyngeal mucosa (with hoarseness), dryness of skin (with dermatitis, scaling, thinning, erythema, pruritus), epidermal fragility (trauma may cause blistering), haematuria, headache, myalgia, neutropenia, proteinuria, raised blood-glucose concentration, raised plasma-triglyceride concentration, raised serum-cholesterol concentration (with reduced high-density lipoprotein concentration), raised serum-transaminase concentration, thrombocytopenia, thrombocytosis,
              </p>
              <p>
                <strong>rare:</strong> aggressive behaviour, alopecia, anxiety, depression, mood changes, skin reactions,
              </p>
              <p>
                <strong>veryRare:</strong> acne fulminans, allergic vasculitis, arthritis, benign intracranial hypertension, blurred vision, bone changes following long-term administration, calcification of tendons and ligaments following long-term administration, cataracts, colour blindness, convulsions, corneal opacities, decreased night vision, decreased tolerance to contact lenses, diabetes mellitus, dizziness, drowsiness, early epiphyseal closure following long-term administration, exacerbation of acne, gastrointestinal haemorrhage, glomerulonephritis, Gram-positive infections of skin and mucous membranes, granulomatous lesions, haemorrhagic diarrhoea, hepatitis, hirsutism, hyperuricaemia, impaired hearing, increased sweating, inflammatory bowel disease, keratitis, lymphadenopathy, malaise, nail dystrophy, nausea, papilloedema, paronychia, photophobia, photosensitivity, psychosis, raised serum-creatine kinase concentration, reduced bone density following long-term administration, skeletal hyperostosis following long-term administration, skin hyperpigmentation, suicidal ideation, tendinitis, visual disturbances,
              </p>
              <p>
                <strong>notKnown:</strong> Stevens-Johnson syndrome, toxic epidermal necrolysis, blistering of skin, burning, crusting of skin, dry or peeling skin, erythema, eye irritation, increased sensitivity to UVB light or sunlight, oedema, pruritus, stinging,
              </p>
        
            <section class="advice">
                <h3>Management of side-effects</h3>
              <p>Risk of pancreatitis if triglycerides above 9&#8239;mmol/litre&#8212;discontinue if uncontrolled hypertriglyceridaemia or pancreatitis.</p><p>Psychiatric side-effects require expert referral.</p><p>Discontinue treatment if skin peeling severe or haemorrhagic diarrhoea develops.</p><p>Visual disturbances require expert referral and possible withdrawal.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Warn patient to avoid wax epilation (risk of epidermal stripping), dermabrasion, and laser skin treatments (risk of scarring) during treatment and for at least 6 months after stopping; patient should avoid exposure to UV light (including sunlight) and use sunscreen and emollient (including lip balm) preparations from the start of treatment.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Patients should be warned that some redness and skin peeling can occur initially but settles with time. If undue irritation occurs, the frequency of application should be reduced or treatment suspended until the reaction subsides; if irritation persists, discontinue treatment. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop.</p><p>If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Patients and carers should be told how to recognise signs and symptoms of psychiatric disorders such as depression, anxiety, and rarely suicidal thoughts.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With oral use:</strong>
            avoid blood donation during treatment and for at least 1 month after treatment
          </li>
          <li>
              <strong>With oral use:</strong>
            diabetes
          </li>
          <li>
              <strong>With oral use:</strong>
            dry eye syndrome (associated with risk of keratitis)
          </li>
          <li>
              <strong>With oral use:</strong>
            history of depression
          </li>
          <li>
              <strong>With oral use:</strong>
            monitor for depression
          </li>
          <li>
              <strong>With topical use:</strong>
            allow peeling (resulting from other irritant treatments) to subside before using a topical retinoid
          </li>
          <li>
              <strong>With topical use:</strong>
            alternating a preparation that causes peeling with a topical retinoid may give rise to contact dermatitis (reduce frequency of retinoid application)
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid accumulation in angles of the nose
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid exposure to UV light (including sunlight, solariums)
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid in severe acne involving large areas
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid use of topical retinoids with abrasive cleaners, comedogenic or astringent cosmetics
          </li>
          <li>
              <strong>With topical use:</strong>
            caution in sensitive areas such as the neck
          </li>
          <li>
              <strong>With topical use:</strong>
            personal or familial history of non-melanoma skin cancer
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Pregnancy prevention</p>
              <p>Effective contraception must be used.</p><p>In women of child-bearing potential, exclude pregnancy up to 3 days before treatment (start treatment on day 2 or 3 of menstrual cycle), every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment&#8212;perform pregnancy test in the first 3 days of the menstrual cycle. Women must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception, but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone, but can be used in conjunction with other contraceptive methods. Each prescription for isotretinoin should be limited to a supply of up to 30 days&#8217; treatment and dispensed within 7 days of the date stated on the prescription; repeat prescriptions or faxed prescriptions are not acceptable. Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use</h3>
              <p>Females of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective).</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Measure hepatic function and serum lipids before treatment, 1 month after starting and then every 3 months (reduce dose or discontinue if transaminase or serum lipids persistently raised).</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Isotretinoin is an isomer of tretinoin.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ISOTRETINOIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76001"><a href="../medicinalForm/PHP76001.html" data-target="#PHP76001" data-action="load">Capsule</a></div>
            <div id="PHP75992"><a href="../medicinalForm/PHP75992.html" data-target="#PHP75992" data-action="load">Gel</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
